Citations

Showing 10 of 108083 citations.

Benefits and challenges in implementation of artificial intelligence in colonoscopy: World Endoscopy Organization position statement
Hassan, Cesare , Halvorsen, Natalie , Berzin, Tyler M. , Renteln, Daniel von , Hewett, David G. , Repici, Alessandro , Ramchandani, Mohan , Khatry, Maryam Al , Yu, Honggang , Saito, Yutaka , Misawa, Masashi , Parasa, Sravanthi , Matsubayashi, Carolina Ogawa , Ogata, Haruhiko , Tajiri, Hisao, Ahmad, Omer F. , Rex, Douglas K. , Berzin, Tyler M , Hewett, David G , Wang, Pu , Saito, Yutaka , Misawa, Masashi , Matsubayashi, Carolina Ogawa , Hassan, Cesare , Mori, Yuichi , East, James E. , Byrne, Michael F. , Kudo, Shin‐ei , Wang, Pu , Pausawasdi, Nonthalee , Dekker, Evelien , Sharma, Prateek

Mayo Clinic

Digestive Endoscopy | February 7, 2023 | Volume: 35 | Issue: 4 | Pages: 422-429

10.1111/den.14531 | PMID 36749036 Get It

The number of artificial intelligence (AI) tools for colonoscopy on the market is increasing with supporting clinical evidence. Nevertheless, their implementation is not going smoothly for a variety of reasons, including lack of data on clinical benefits and cost‐effectiveness, lack of trustworthy guidelines, uncertain indications, and cost for implementation. To address this issue and better guide practitioners, the World Endoscopy Organization (WEO) has provided its perspective about the status of AI in colonoscopy as the position statement. WEO Position Statement: Statement 1.1: Computer‐aided detection (CADe) for colorectal polyps is likely to improve colonoscopy effectiveness by reducing adenoma miss rates and thus increase adenoma detection; Statement 1.2: In the short term, use of CADe is likely to increase health‐care costs by detecting more adenomas; Statement 1.3: In the long term, the increased cost by CADe could be balanced by savings in costs related to cancer treatment (surgery, chemotherapy, palliative care) due to CADe‐related cancer prevention; Statement 1.4: Health‐care delivery systems and authorities should evaluate the cost‐effectiveness of CADe to support its use in clinical practice; Statement 2.1: Computer‐aided diagnosis (CADx) for diminutive polyps (≤5 mm), when it has sufficient accuracy, is expected to reduce health‐care costs by reducing polypectomies, pathological examinations, or both; Statement 2.2: Health‐care delivery systems and authorities should evaluate the cost‐effectiveness of CADx to support its use in clinical practice; Statement 3: We recommend that a broad range of high‐quality cost‐effectiveness research should be undertaken to understand whether AI implementation benefits populations and societies in different health‐care systems.
Clinical Images: IgG4‐related disease: a giant cell arteritis mimic
Kaymakci, Mahmut , Elfishawi, Mohanad , Koster, Matthew J. , Hurst, Philip D., Elfishawi, M , Koster, Matthew J , Kaymakci, Mahmut S , Warrington, Kenneth J.

Mayo Clinic

Arthritis & Rheumatology | February 7, 2023 | Volume: 75 | Issue: 7 | Pages: 1262-1262

10.1002/art.42469 | PMID 36749679 Get It

Advancements and Technical Considerations for Extracellular Vesicle Isolation and Biomarker Identification in Glioblastoma
Garcia, Luz Milbeth Cumba, Bouchal, Samantha M. , Bauman, Megan M. J. , Cumba Garcia, Luz M, Bauman, Megan , Bouchal, Samantha M , Parney, Ian F.

Mayo Clinic

Neurosurgery | February 7, 2023 | Volume: 93 | Issue: 1 | Pages: 33-42

10.1227/neu.0000000000002393 | PMID 36749103 Get It

Extracellular vesicles (EVs) are membrane-bound particles released by all cells. Previous research has found that these microscopic vesicles contribute to intercellular signaling and communication. EVs carry a variety of cargo, including nucleic acids, proteins, metabolites, and lipids. The composition of EVs varies based on cell of origin. Therefore, EVs can serve as an important biomarker in the diagnosis and treatment of various cancers. EVs derived from glioblastoma (GBM) cells carry biomarkers, which could serve as the basis for a potential diagnostic strategy known as liquid biopsy. Multiple EV isolation techniques exist, including ultrafiltration, size exclusion chromatography, flow field-flow fractionation, sequential filtration, differential ultracentrifugation, and density-gradient ultracentrifugation. Recent and ongoing work aims to identify cellular markers to distinguish GBM-derived EVs from those released by noncancerous cells. Strategies include proteomic analysis of GBM EVs, identification of GBM-specific metabolites, and use of Food and Drug Administration-approved 5-aminolevulinic acid—an oral agent that causes fluorescence of GBM cells—to recognize GBM EVs in a patient's blood. In addition, accurately and precisely monitoring changes in EV cargo concentrations could help differentiate between pseudoprogression and GBM recurrence, thus preventing unnecessary surgical interventions.
Opportunistic screening for low bone density using abdominopelvic computed tomography scans
Tariq, Amara , Patel, Bhavik N. , Fahrenholtz, Samuel J. , Banerjee, Imon , Sensakovic, William F. , Banerjee, Imon

Mayo Clinic

Medical Physics | February 7, 2023 | Volume: 50 | Issue: 7 | Pages: 4296-4307

10.1002/mp.16230 | PMID 36748265 Get It

AbstractBackgroundWhile low bone density is a major burden on US health system, current osteoporosis screening guidelines by the US Preventive Services Task Force are limited to women aged ≥65 and all postmenopausal women with certain risk factors. Even within recommended screening groups, actual screening rates are low (<26%) and vary across socioeconomic groups. The proposed model can opportunistically screen patients using abdominal CT studies for low bone density who may otherwise go undiagnosed.PurposeTo develop an artificial intelligence (AI) model for opportunistic screening of low bone density using both contrast and non‐contrast abdominopelvic computed tomography (CT) exams, for the purpose of referral to traditional bone health management, which typically begins with dual energy X‐ray absorptiometry (DXA).MethodsWe collected 6083 contrast‐enhanced CT imaging exams paired with DXA exams within ±6 months documented between May 2015 and August 2021 in a single institution with four major healthcare practice regions. Our fusion AI pipeline receives the coronal and axial plane images of a contrast enhanced abdominopelvic CT exam and basic patient demographics (age, gender, body cross section lengths) to predict risk of low bone mass. The models were trained on lumbar spine T‐scores from DXA exams and tested on multi‐site imaging exams. The model was again tested in a prospective group (N = 344) contrast‐enhanced and non‐contrast‐enhanced studies.ResultsThe models were evaluated on the same test set (1208 exams)—(1) Baseline model using demographic factors from electronic medical records (EMR) ‐ 0.7 area under the curve of receiver operator characteristic (AUROC); Imaging based models: (2) axial view ‐ 0.83 AUROC; (3) coronal view‐ 0.83 AUROC; (4) Fusion model—Imaging + demographic factors ‐ 0.86 AUROC. The prospective test yielded one missed positive DXA case with a hip prosthesis among 23 positive contrast‐enhanced CT exams and 0% false positive rate for non‐contrast studies. Both positive cases among non‐contrast enhanced CT exams were successfully detected. While only about 8% patients from prospective study received a DXA exam within 2 years, about 30% were detected with low bone mass by the fusion model, highlighting the need for opportunistic screening.ConclusionsThe fusion model, which combines two planes of CT images and EMRs data, outperformed individual models and provided a high, robust diagnostic performance for opportunistic screening of low bone density using contrast and non‐contrast CT exams. This model could potentially improve bone health risk assessment with no additional cost. The model's handling of metal implants is an ongoing effort.
Expectations and clinical meaningfulness of randomized controlled trials
Petersen, Ronald C. , Aisen, Paul , Andrews, J. Scott , Matthews, Brandy R., Siemers, Eric , Weber, Christopher J., Carrillo, María C. , Atri, Alireza , Rentz, Dorene M.

Mayo Clinic

Alzheimer's & Dementia | February 7, 2023 | Volume: 19 | Issue: 6 | Pages: 2730-2736

10.1002/alz.12959 | PMID 36748826 Get It

Abstract Alzheimer's disease (AD) clinical trials are designed and powered to detect the impact of a therapeutic intervention, and there has been considerable discussion on what constitutes a clinically meaningful change in those receiving treatment versus placebo. The pathology of AD is complex, beginning many years before clinical symptoms are detectable, with multiple potential opportunities for therapeutic engagement. Introducing treatment strategies early in the disease and assessing meaningful change over the course of an 18‐month clinical trial are critical to understanding the value to an effective intervention. With new clinical trial data expected soon on emerging therapeutics from several AD studies, the Alzheimer's Association convened a work group of experts to discuss key considerations for interpreting data from cognitive and functional measures and what is considered a clinically meaningful benefit or meaningful slowing of this fatal disease. Our expectations of outcomes from therapeutic interventions in AD may need to be modified.
QSM Throughout the Body
Dimov, Alexey , Li, Jiahao , Nguyen, Thanh D. , Roberts, Alexandra , Spincemaille, Pascal , Straub, Sina , Zun, Zungho , Prince, Martin R. , Wang, Yi , Dimov, Alexey V , Roberts, Alexandra G , Spincemaille, Pascal , Straub, Sina

Mayo Clinic

Journal of Magnetic Resonance Imaging | February 7, 2023 | Volume: 57 | Issue: 6 | Pages: 1621-1640

10.1002/jmri.28624 | PMID 36748806 Get It

Magnetic materials in tissue, such as iron, calcium, or collagen, can be studied using quantitative susceptibility mapping (QSM). To date, QSM has been overwhelmingly applied in the brain, but is increasingly utilized outside the brain. QSM relies on the effect of tissue magnetic susceptibility sources on the MR signal phase obtained with gradient echo sequence. However, in the body, the chemical shift of fat present within the region of interest contributes to the MR signal phase as well. Therefore, correcting for the chemical shift effect by means of water‐fat separation is essential for body QSM. By employing techniques to compensate for cardiac and respiratory motion artifacts, body QSM has been applied to study liver iron and fibrosis, heart chamber blood and placenta oxygenation, myocardial hemorrhage, atherosclerotic plaque, cartilage, bone, prostate, breast calcification, and kidney stone.
Atomic Force Microscopy Micro-Indentation Methods for Determining the Elastic Modulus of Murine Articular Cartilage
Arnold, Katherine M. , Sicard, Delphine , Tschumperlin, Daniel J. , Westendorf, Jennifer J. , Westendorf, Jennifer J

Mayo Clinic

Sensors | February 7, 2023 | Volume: 23 | Issue: 4 | Pages: 1835

10.3390/s23041835 | PMID 36850434 Get It

The mechanical properties of biological tissues influence their function and can predict degenerative conditions before gross histological or physiological changes are detectable. This is especially true for structural tissues such as articular cartilage, which has a primarily mechanical function that declines after injury and in the early stages of osteoarthritis. While atomic force microscopy (AFM) has been used to test the elastic modulus of articular cartilage before, there is no agreement or consistency in methodologies reported. For murine articular cartilage, methods differ in two major ways: experimental parameter selection and sample preparation. Experimental parameters that affect AFM results include indentation force and cantilever stiffness; these are dependent on the tip, sample, and instrument used. The aim of this project was to optimize these experimental parameters to measure murine articular cartilage elastic modulus by AFM micro-indentation. We first investigated the effects of experimental parameters on a control material, polydimethylsiloxane gel (PDMS), which has an elastic modulus on the same order of magnitude as articular cartilage. Experimental parameters were narrowed on this control material, and then finalized on wildtype C57BL/6J murine articular cartilage samples that were prepared with a novel technique that allows for cryosectioning of epiphyseal segments of articular cartilage and long bones without decalcification. This technique facilitates precise localization of AFM measurements on the murine articular cartilage matrix and eliminates the need to separate cartilage from underlying bone tissues, which can be challenging in murine bones because of their small size. Together, the new sample preparation method and optimized experimental parameters provide a reliable standard operating procedure to measure microscale variations in the elastic modulus of murine articular cartilage.
A three‐gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia
Wang, Yu‐Hung , Yao, Chi‐Yuan , Lin, Chien‐Chin , Gurashi, Kristian , Amaral, Fabio M. R. , Bossenbroek, Hasse M , Jerez, Andrés , Somervaille, Tim C. P. , Binder, Moritz , Patnaik, Mrinal M. , Chou, Wen‐Chien , Batta, Kiran , Wiseman, Daniel H. , Chou, Wen-Chien , Wiseman, Daniel H , Binder, Moritz , Jerez, Andrés , Wang, Yu-Hung , Somervaille, Tim C.P. , Hou, Hsin‐An , Tien, Hwei‐Fang

Mayo Clinic

British Journal of Haematology | February 7, 2023 | Volume: 201 | Issue: 2 | Pages: 302-307

10.1111/bjh.18681 | PMID 36746431 Get It

SummaryLeukaemic stem cell (LSC) gene expression has recently been linked to prognosis in patients with acute myeloid leukaemia (17‐gene LSC score, LSC‐17) and myelodysplastic syndromes. Although chronic myelomonocytic leukaemia (CMML) is regarded as a stem cell disorder, the clinical and biological impact of LSCs on CMML patients remains elusive. Making use of multiple independent validation cohorts, we here describe a concise three‐gene expression signature (LSC‐3, derived from the LSC‐17 score) as an independent and robust prognostic factor for leukaemia‐free and overall survival in CMML. We propose that LSC‐3 could be used to supplement existing risk stratification systems, to improve prognostic performance and guide management decisions.
Adapting to Evolving Technologies and Treatment Guidelines in a Procedural Trial
Meschia, James F. , Lal, Brajesh K. , Roubin, Gary S. , Turan, Tanya N. , Benson, Richard , Carman, Kaley , Brott, Thomas G. , Lal, Brajesh , Roubin, Gary , Howard, Virginia J , Benson, Richard T , Carman, Kaley , Brott, Thomas G , Meschia, James F , Howard, Virginia J. , Howard, George

Mayo Clinic

Neurology | February 7, 2023 | Volume: 100 | Issue: 22 | Pages: 1060-1066

10.1212/wnl.0000000000207075 | PMID 36746636 Get It

Peripartum anesthetic management in patients with Ebstein anomaly: a case series
Gurrieri, Carmelina , Sharpe, Emily E. , Connolly, Heidi M. , Rose, Carl H., Arendt, Katherine W. , Sharpe, Emily E

Mayo Clinic

Baylor University Medical Center Proceedings | February 6, 2023 | Volume: 36 | Issue: 3 | Pages: 346-350

10.1080/08998280.2023.2169561 | PMID 37091760 Get It